Obstructive sleep apnea (OSA) is associated with dyslipidemia and increased cardiovascular risk. We assessed the effects of apolipoprotein E (APOE) genotype on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and lipid subclasses (separated by gradient gel electrophoresis) in patients with OSA. Stable patients (n = 181) prospectively recruited underwent full polysomnography. Both LDL particle size and LDL I proportion were reduced from ∊3∊3 homozygotes to ∊2 carriers and to ∊4 carriers (analysis of variance: P = .024; P = .040, respectively); carriers of the ∊4 allele of the APOE genotype had significantly lower LDL particle size and LDL I proportion compared to ∊3∊3 homozygotes (P < .05 for both comparisons). Insulin resistance increased from patients with no OSA to those with mild–moderate and to those with severe OSA (P < .001). In multivariate analysis, LDL size was independently predicted by APOE genotype, male gender, and the presence of metabolic syndrome (MetS; P = .001, P = .020, P = .027, respectively). The HDL particle size was not affected by APOE genotype. Our data demonstrate that both the ∊4 APOE genotype and MetS are independently related to smaller LDL size in patients with OSA.
MarinJMCarrizoSJVicenteEAgustiAG. Long-term cardiovascular outcomes in men with obstructive sleep apnea–hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365(9464):1046–1053.
2.
NewmanABNietoFJGuidryU; Sleep Heart Health Study Research Group. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol. 2001;154(1):50–59.
3.
KendzerskaTMollayevaTGershonASLeungRSHawkerGTomlinsonG. Untreated obstructive sleep apnea and the risk for serious long-term adverse outcomes: a systematic review. Sleep Med Rev. 2014;18(1):49–59.
4.
Jean-LouisGZiziFBrownDOgedegbeGBorerJMcFarlaneS. Obstructive sleep apnea and cardiovascular disease: evidence and underlying mechanisms. Minerva Pneumol. 2009;48(4):277–293.
5.
McArdleNHillmanDBeilinLWattsG. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med. 2007;175(2):190–195.
6.
RizzoMBerneisKZeljkovicAVekicJ. Should we routinely measure low-density and high-density lipoprotein subclasses?Clin Lab. 2009;55(11-12):421–429.
SopkovaZBerneisKRizzoM. Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea. Angiology. 2012;63(8):617–621.
9.
MikhailidisDPElisafMSRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol2011;9(5):533–571.
10.
MikhailidisDPElisafMSRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–532.
11.
LuysterFSKipKEDrumhellerOJ. Sleep apnea is related to the atherogenic phenotype, lipoprotein subclass B. J Clin Sleep Med. 2012;8(12):155–161.
12.
LusisAJFogelmanAMFonarowGC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation. 2004;110(14):1868–1873.
13.
ChasmanDIParéGMoraS. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009;5(11):e1000730.
14.
OkumuraKMatsuiHKawakamiK. Relationship between the apolipoprotein E and angiotensin-converting enzyme genotypes and LDL particle size in Japanese subjects. Clin Chim Acta. 1999;285(1-2):91–103.
15.
BarbagalloCMPolizziFSeverinoM. ApoE polymorphism in a small Mediterranean island: relationships with plasma lipids, lipoproteins and LDL particle size. Eur J Epidemiol. 2001;17(8):707–713.
16.
AkanjiAOSureshCGFataniaHRAl-RadwanRZubaidM. Associations of apolipoprotein E polymorphism with low-density lipoprotein size and subfraction profiles in Arab patients with coronary heart disease. Metabolism. 2007;56(4):484–490.
17.
BennetAMDi AngelantonioEYeZ. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298(11):1300–1311.
18.
Carvalho-WellsALJacksonKGGillR. Interactions between age and apoE genotype on fasting and postprandial triglycerides levels. Atherosclerosis. 2010;212(2):481–487.
19.
KoflerBMMilesEACurtisP. Apolipoprotein E genotype and the cardiovascular disease risk phenotype: impact of sex and adiposity (the FINGEN study). Atherosclerosis. 2012;221(2):467–470.
20.
TiskoRSopkovaZHabalovaV. Effects of apolipoprotein E genotype on serum lipids in obstructive sleep apnoea. Eur Respir J. 2014;43(4):1097–1105.
21.
AlbertiKGEckelRHGrundySM; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
22.
BerryRBBudhirajaRGottliebDJ. American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012;8(5):597–619.
23.
MatthewsDRHoskerJPRudenskiASNaylorBATreacherDFTurnerRC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
24.
RainwaterDLMoorePHJrGamboaIO. Improved method for making nondenaturing composite gradient gels for the electrophoretic separation of lipoproteins. J Lipid Res. 2004;45(4):773–775.
25.
VekicJTopicAZeljkovicAJelic-IvanovicZSpasojevic-KalimanovskaV. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem. 2007;40(5-6):310–316.
26.
ZeljkovicAVekicJSpasojevic-KalimanovskaV. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis. 2010;210(2):548–554.
27.
PafiliKSteiropoulosPPapanasN. The relationship between obstructive sleep apnoea and coronary heart disease. Curr Opin Cardiol. 2015;30(4):439–446.
28.
RizzoMBerneisK. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006;99(1):1–14.
29.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
30.
GaziITsimihodimosVFilippatosTBairaktariETselepisADElisafM. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism. 2006;55(7):885–891.
31.
TsompanidiEMBrinkmeierMSFotiadouEHGiakoumiSMKypreosKE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis. 2010;208(1):3–9.
32.
RadwanZHWangXWaqarF. Comprehensive evaluation of the association of APOE genetic variation with plasma lipoprotein traits in U.S. whites and African blacks. PLoS One. 2014;9(12):e114618.
33.
ChoYLeeSGJeeSHKimJH. Hypertriglyceridemia is a major factor associated with elevated levels of small dense LDL cholesterol in patients with metabolic syndrome. Ann Lab Med. 2015;35(6):586–594.
34.
NikolicDKatsikiNMontaltoGIsenovicERMikhailidisDPRizzoM. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013;5(3):928–948.
35.
DutheilFWaltherGChapierR. Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet - the RESOLVE trial. Lipids Health Dis. 2014;13(2):112.
36.
HagbergJMWilundKRFerrellRE. APOE gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics. 2000;4(2):101–108.
37.
VarvarigouVDahabrehIJMalhotraAKalesSN. A review of genetic association studies of obstructive sleep apnea: field synopsis and meta-analysis. Sleep. 2011;34(11):1461–1468.
38.
UyrumEBalbayOAnnakkayaANGulec BalbayESilanFArbakP. The relationship between obstructive sleep apnea syndrome and apolipoprotein E genetic variants. Respiration. 2015;89(3):195–200.
39.
PunjabiNMPolotskyVY. Disorders of glucose metabolism in sleep apnea. J Appl Physiol. 2005;99(5):1998–2007.
40.
LamJCLamBLamCL. Obstructive sleep apnea and the metabolic syndrome in community/based Chinese adults in Hong Kong. Respir Med. 2006;100(6):980–987.
41.
DragerLFLopesHFMaki-NunesC. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One. 2010;5(8):e12065.
